Global Human Genetically Engineered Vaccine Market Growth 2026-2032
The global Human Genetically Engineered Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Human Genetically Engineered Vaccine Industry Forecast? looks at past sales and reviews total world Human Genetically Engineered Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Human Genetically Engineered Vaccine sales for 2026 through 2032. With Human Genetically Engineered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Genetically Engineered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Genetically Engineered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Genetically Engineered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Genetically Engineered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Genetically Engineered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Genetically Engineered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Genetically Engineered Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Human Genetically Engineered Vaccine Industry Forecast? looks at past sales and reviews total world Human Genetically Engineered Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Human Genetically Engineered Vaccine sales for 2026 through 2032. With Human Genetically Engineered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Genetically Engineered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Genetically Engineered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Genetically Engineered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Genetically Engineered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Genetically Engineered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Genetically Engineered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Genetically Engineered Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Genetic Recombinant Vaccine
- Recombinant Subunit Vaccines
- Genetic Vaccine
- Hepatitis E
- Human Papillomavirus (HPV)
- Rotavirus
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Merck
- GSK
- Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
- Walvax Biotechnology Co., Ltd.
- Bharat Biotech
- Chengdu Kanghua Biological Products Co., Ltd.
- South China Vaccine Corporation Limited
- Beijing Health Guard Biotechnology Inc.
- CSL Limited
- Emergent BioSolutions
- Sanofi Pasteur
- Serum Institute
- What is the 10-year outlook for the global Human Genetically Engineered Vaccine market?
- What factors are driving Human Genetically Engineered Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Human Genetically Engineered Vaccine market opportunities vary by end market size?
- How does Human Genetically Engineered Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Genetically Engineered Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Human Genetically Engineered Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Human Genetically Engineered Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Human Genetically Engineered Vaccine Segment by Type
2.2.1 Genetic Recombinant Vaccine
2.2.2 Recombinant Subunit Vaccines
2.2.3 Genetic Vaccine
2.2.4 Human Genetically Engineered Vaccine Sales by Type
2.2.4.1 Global Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Human Genetically Engineered Vaccine Sale Price by Type (2021-2026)
2.3 Human Genetically Engineered Vaccine Segment by Application
2.3.1 Hepatitis E
2.3.2 Human Papillomavirus (HPV)
2.3.3 Rotavirus
2.3.4 Others
2.3.5 Human Genetically Engineered Vaccine Sales by Application
2.3.5.1 Global Human Genetically Engineered Vaccine Sale Market Share by Application (2021-2026)
2.3.5.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Human Genetically Engineered Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Human Genetically Engineered Vaccine Breakdown Data by Company
3.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Human Genetically Engineered Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Human Genetically Engineered Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Human Genetically Engineered Vaccine Revenue by Company (2021-2026)
3.2.2 Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Human Genetically Engineered Vaccine Sale Price by Company
3.4 Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Genetically Engineered Vaccine Product Location Distribution
3.4.2 Players Human Genetically Engineered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Genetically Engineered Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Human Genetically Engineered Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Human Genetically Engineered Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Human Genetically Engineered Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Human Genetically Engineered Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Human Genetically Engineered Vaccine Sales Growth
4.4 APAC Human Genetically Engineered Vaccine Sales Growth
4.5 Europe Human Genetically Engineered Vaccine Sales Growth
4.6 Middle East & Africa Human Genetically Engineered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Genetically Engineered Vaccine Sales by Country
5.1.1 Americas Human Genetically Engineered Vaccine Sales by Country (2021-2026)
5.1.2 Americas Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
5.2 Americas Human Genetically Engineered Vaccine Sales by Type (2021-2026)
5.3 Americas Human Genetically Engineered Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Genetically Engineered Vaccine Sales by Region
6.1.1 APAC Human Genetically Engineered Vaccine Sales by Region (2021-2026)
6.1.2 APAC Human Genetically Engineered Vaccine Revenue by Region (2021-2026)
6.2 APAC Human Genetically Engineered Vaccine Sales by Type (2021-2026)
6.3 APAC Human Genetically Engineered Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Genetically Engineered Vaccine by Country
7.1.1 Europe Human Genetically Engineered Vaccine Sales by Country (2021-2026)
7.1.2 Europe Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
7.2 Europe Human Genetically Engineered Vaccine Sales by Type (2021-2026)
7.3 Europe Human Genetically Engineered Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Genetically Engineered Vaccine by Country
8.1.1 Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine
10.3 Manufacturing Process Analysis of Human Genetically Engineered Vaccine
10.4 Industry Chain Structure of Human Genetically Engineered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Genetically Engineered Vaccine Distributors
11.3 Human Genetically Engineered Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Genetically Engineered Vaccine Market Size Forecast by Region
12.1.1 Global Human Genetically Engineered Vaccine Forecast by Region (2027-2032)
12.1.2 Global Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Human Genetically Engineered Vaccine Forecast by Type (2027-2032)
12.7 Global Human Genetically Engineered Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
13.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
13.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business Overview
13.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
13.5 Walvax Biotechnology Co., Ltd.
13.5.1 Walvax Biotechnology Co., Ltd. Company Information
13.5.2 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Walvax Biotechnology Co., Ltd. Main Business Overview
13.5.5 Walvax Biotechnology Co., Ltd. Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Chengdu Kanghua Biological Products Co., Ltd.
13.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.7.2 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.7.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.8 South China Vaccine Corporation Limited
13.8.1 South China Vaccine Corporation Limited Company Information
13.8.2 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 South China Vaccine Corporation Limited Main Business Overview
13.8.5 South China Vaccine Corporation Limited Latest Developments
13.9 Beijing Health Guard Biotechnology Inc.
13.9.1 Beijing Health Guard Biotechnology Inc. Company Information
13.9.2 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Beijing Health Guard Biotechnology Inc. Main Business Overview
13.9.5 Beijing Health Guard Biotechnology Inc. Latest Developments
13.10 CSL Limited
13.10.1 CSL Limited Company Information
13.10.2 CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSL Limited Main Business Overview
13.10.5 CSL Limited Latest Developments
13.11 Emergent BioSolutions
13.11.1 Emergent BioSolutions Company Information
13.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Emergent BioSolutions Main Business Overview
13.11.5 Emergent BioSolutions Latest Developments
13.12 Sanofi Pasteur
13.12.1 Sanofi Pasteur Company Information
13.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sanofi Pasteur Main Business Overview
13.12.5 Sanofi Pasteur Latest Developments
13.13 Serum Institute
13.13.1 Serum Institute Company Information
13.13.2 Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Serum Institute Main Business Overview
13.13.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Genetically Engineered Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Human Genetically Engineered Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Human Genetically Engineered Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Human Genetically Engineered Vaccine Segment by Type
2.2.1 Genetic Recombinant Vaccine
2.2.2 Recombinant Subunit Vaccines
2.2.3 Genetic Vaccine
2.2.4 Human Genetically Engineered Vaccine Sales by Type
2.2.4.1 Global Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Human Genetically Engineered Vaccine Sale Price by Type (2021-2026)
2.3 Human Genetically Engineered Vaccine Segment by Application
2.3.1 Hepatitis E
2.3.2 Human Papillomavirus (HPV)
2.3.3 Rotavirus
2.3.4 Others
2.3.5 Human Genetically Engineered Vaccine Sales by Application
2.3.5.1 Global Human Genetically Engineered Vaccine Sale Market Share by Application (2021-2026)
2.3.5.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Human Genetically Engineered Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Human Genetically Engineered Vaccine Breakdown Data by Company
3.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Human Genetically Engineered Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Human Genetically Engineered Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Human Genetically Engineered Vaccine Revenue by Company (2021-2026)
3.2.2 Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Human Genetically Engineered Vaccine Sale Price by Company
3.4 Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Genetically Engineered Vaccine Product Location Distribution
3.4.2 Players Human Genetically Engineered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Genetically Engineered Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Human Genetically Engineered Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Human Genetically Engineered Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Human Genetically Engineered Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Human Genetically Engineered Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Human Genetically Engineered Vaccine Sales Growth
4.4 APAC Human Genetically Engineered Vaccine Sales Growth
4.5 Europe Human Genetically Engineered Vaccine Sales Growth
4.6 Middle East & Africa Human Genetically Engineered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Genetically Engineered Vaccine Sales by Country
5.1.1 Americas Human Genetically Engineered Vaccine Sales by Country (2021-2026)
5.1.2 Americas Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
5.2 Americas Human Genetically Engineered Vaccine Sales by Type (2021-2026)
5.3 Americas Human Genetically Engineered Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Genetically Engineered Vaccine Sales by Region
6.1.1 APAC Human Genetically Engineered Vaccine Sales by Region (2021-2026)
6.1.2 APAC Human Genetically Engineered Vaccine Revenue by Region (2021-2026)
6.2 APAC Human Genetically Engineered Vaccine Sales by Type (2021-2026)
6.3 APAC Human Genetically Engineered Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Genetically Engineered Vaccine by Country
7.1.1 Europe Human Genetically Engineered Vaccine Sales by Country (2021-2026)
7.1.2 Europe Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
7.2 Europe Human Genetically Engineered Vaccine Sales by Type (2021-2026)
7.3 Europe Human Genetically Engineered Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Genetically Engineered Vaccine by Country
8.1.1 Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine
10.3 Manufacturing Process Analysis of Human Genetically Engineered Vaccine
10.4 Industry Chain Structure of Human Genetically Engineered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Genetically Engineered Vaccine Distributors
11.3 Human Genetically Engineered Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Genetically Engineered Vaccine Market Size Forecast by Region
12.1.1 Global Human Genetically Engineered Vaccine Forecast by Region (2027-2032)
12.1.2 Global Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Human Genetically Engineered Vaccine Forecast by Type (2027-2032)
12.7 Global Human Genetically Engineered Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
13.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
13.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business Overview
13.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
13.5 Walvax Biotechnology Co., Ltd.
13.5.1 Walvax Biotechnology Co., Ltd. Company Information
13.5.2 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Walvax Biotechnology Co., Ltd. Main Business Overview
13.5.5 Walvax Biotechnology Co., Ltd. Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Chengdu Kanghua Biological Products Co., Ltd.
13.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.7.2 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.7.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.8 South China Vaccine Corporation Limited
13.8.1 South China Vaccine Corporation Limited Company Information
13.8.2 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 South China Vaccine Corporation Limited Main Business Overview
13.8.5 South China Vaccine Corporation Limited Latest Developments
13.9 Beijing Health Guard Biotechnology Inc.
13.9.1 Beijing Health Guard Biotechnology Inc. Company Information
13.9.2 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Beijing Health Guard Biotechnology Inc. Main Business Overview
13.9.5 Beijing Health Guard Biotechnology Inc. Latest Developments
13.10 CSL Limited
13.10.1 CSL Limited Company Information
13.10.2 CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CSL Limited Main Business Overview
13.10.5 CSL Limited Latest Developments
13.11 Emergent BioSolutions
13.11.1 Emergent BioSolutions Company Information
13.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Emergent BioSolutions Main Business Overview
13.11.5 Emergent BioSolutions Latest Developments
13.12 Sanofi Pasteur
13.12.1 Sanofi Pasteur Company Information
13.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sanofi Pasteur Main Business Overview
13.12.5 Sanofi Pasteur Latest Developments
13.13 Serum Institute
13.13.1 Serum Institute Company Information
13.13.2 Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Serum Institute Main Business Overview
13.13.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Genetically Engineered Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Human Genetically Engineered Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Genetic Recombinant Vaccine
Table 4. Major Players of Recombinant Subunit Vaccines
Table 5. Major Players of Genetic Vaccine
Table 6. Global Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 7. Global Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Human Genetically Engineered Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Human Genetically Engineered Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Human Genetically Engineered Vaccine Sale by Application (2021-2026) & (K Units)
Table 12. Global Human Genetically Engineered Vaccine Sale Market Share by Application (2021-2026)
Table 13. Global Human Genetically Engineered Vaccine Revenue by Application (2021-2026) & ($ million)
Table 14. Global Human Genetically Engineered Vaccine Revenue Market Share by Application (2021-2026)
Table 15. Global Human Genetically Engineered Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Human Genetically Engineered Vaccine Sales by Company (2021-2026) & (K Units)
Table 17. Global Human Genetically Engineered Vaccine Sales Market Share by Company (2021-2026)
Table 18. Global Human Genetically Engineered Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2021-2026)
Table 20. Global Human Genetically Engineered Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution and Sales Area
Table 22. Players Human Genetically Engineered Vaccine Products Offered
Table 23. Human Genetically Engineered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Human Genetically Engineered Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Human Genetically Engineered Vaccine Sales Market Share Geographic Region (2021-2026)
Table 28. Global Human Genetically Engineered Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Human Genetically Engineered Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2021-2026)
Table 32. Global Human Genetically Engineered Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Human Genetically Engineered Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 35. Americas Human Genetically Engineered Vaccine Sales Market Share by Country (2021-2026)
Table 36. Americas Human Genetically Engineered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 38. Americas Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 39. APAC Human Genetically Engineered Vaccine Sales by Region (2021-2026) & (K Units)
Table 40. APAC Human Genetically Engineered Vaccine Sales Market Share by Region (2021-2026)
Table 41. APAC Human Genetically Engineered Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 43. APAC Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 44. Europe Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 45. Europe Human Genetically Engineered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 47. Europe Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Human Genetically Engineered Vaccine
Table 53. Key Market Challenges & Risks of Human Genetically Engineered Vaccine
Table 54. Key Industry Trends of Human Genetically Engineered Vaccine
Table 55. Human Genetically Engineered Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Human Genetically Engineered Vaccine Distributors List
Table 58. Human Genetically Engineered Vaccine Customer List
Table 59. Global Human Genetically Engineered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Human Genetically Engineered Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Human Genetically Engineered Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Human Genetically Engineered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Human Genetically Engineered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Human Genetically Engineered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Human Genetically Engineered Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Human Genetically Engineered Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Human Genetically Engineered Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Human Genetically Engineered Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Pfizer Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 75. Pfizer Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Merck Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 80. Merck Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. GSK Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 85. GSK Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 90. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business
Table 92. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
Table 93. Walvax Biotechnology Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 95. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Walvax Biotechnology Co., Ltd. Main Business
Table 97. Walvax Biotechnology Co., Ltd. Latest Developments
Table 98. Bharat Biotech Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 100. Bharat Biotech Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bharat Biotech Main Business
Table 102. Bharat Biotech Latest Developments
Table 103. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 105. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 107. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 108. South China Vaccine Corporation Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 110. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. South China Vaccine Corporation Limited Main Business
Table 112. South China Vaccine Corporation Limited Latest Developments
Table 113. Beijing Health Guard Biotechnology Inc. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 115. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Beijing Health Guard Biotechnology Inc. Main Business
Table 117. Beijing Health Guard Biotechnology Inc. Latest Developments
Table 118. CSL Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 120. CSL Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. CSL Limited Main Business
Table 122. CSL Limited Latest Developments
Table 123. Emergent BioSolutions Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 125. Emergent BioSolutions Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Emergent BioSolutions Main Business
Table 127. Emergent BioSolutions Latest Developments
Table 128. Sanofi Pasteur Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 130. Sanofi Pasteur Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Sanofi Pasteur Main Business
Table 132. Sanofi Pasteur Latest Developments
Table 133. Serum Institute Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 135. Serum Institute Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Serum Institute Main Business
Table 137. Serum Institute Latest Developments
Table 1. Human Genetically Engineered Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Human Genetically Engineered Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Genetic Recombinant Vaccine
Table 4. Major Players of Recombinant Subunit Vaccines
Table 5. Major Players of Genetic Vaccine
Table 6. Global Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 7. Global Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Human Genetically Engineered Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Human Genetically Engineered Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Human Genetically Engineered Vaccine Sale by Application (2021-2026) & (K Units)
Table 12. Global Human Genetically Engineered Vaccine Sale Market Share by Application (2021-2026)
Table 13. Global Human Genetically Engineered Vaccine Revenue by Application (2021-2026) & ($ million)
Table 14. Global Human Genetically Engineered Vaccine Revenue Market Share by Application (2021-2026)
Table 15. Global Human Genetically Engineered Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Human Genetically Engineered Vaccine Sales by Company (2021-2026) & (K Units)
Table 17. Global Human Genetically Engineered Vaccine Sales Market Share by Company (2021-2026)
Table 18. Global Human Genetically Engineered Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2021-2026)
Table 20. Global Human Genetically Engineered Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution and Sales Area
Table 22. Players Human Genetically Engineered Vaccine Products Offered
Table 23. Human Genetically Engineered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Human Genetically Engineered Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Human Genetically Engineered Vaccine Sales Market Share Geographic Region (2021-2026)
Table 28. Global Human Genetically Engineered Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Human Genetically Engineered Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2021-2026)
Table 32. Global Human Genetically Engineered Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Human Genetically Engineered Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 35. Americas Human Genetically Engineered Vaccine Sales Market Share by Country (2021-2026)
Table 36. Americas Human Genetically Engineered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 38. Americas Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 39. APAC Human Genetically Engineered Vaccine Sales by Region (2021-2026) & (K Units)
Table 40. APAC Human Genetically Engineered Vaccine Sales Market Share by Region (2021-2026)
Table 41. APAC Human Genetically Engineered Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 43. APAC Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 44. Europe Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 45. Europe Human Genetically Engineered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 47. Europe Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Human Genetically Engineered Vaccine
Table 53. Key Market Challenges & Risks of Human Genetically Engineered Vaccine
Table 54. Key Industry Trends of Human Genetically Engineered Vaccine
Table 55. Human Genetically Engineered Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Human Genetically Engineered Vaccine Distributors List
Table 58. Human Genetically Engineered Vaccine Customer List
Table 59. Global Human Genetically Engineered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Human Genetically Engineered Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Human Genetically Engineered Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Human Genetically Engineered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Human Genetically Engineered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Human Genetically Engineered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Human Genetically Engineered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Human Genetically Engineered Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Human Genetically Engineered Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Human Genetically Engineered Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Human Genetically Engineered Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Pfizer Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 75. Pfizer Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Merck Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 80. Merck Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. GSK Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 85. GSK Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 90. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business
Table 92. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
Table 93. Walvax Biotechnology Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 95. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Walvax Biotechnology Co., Ltd. Main Business
Table 97. Walvax Biotechnology Co., Ltd. Latest Developments
Table 98. Bharat Biotech Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 100. Bharat Biotech Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bharat Biotech Main Business
Table 102. Bharat Biotech Latest Developments
Table 103. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 105. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 107. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 108. South China Vaccine Corporation Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 110. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. South China Vaccine Corporation Limited Main Business
Table 112. South China Vaccine Corporation Limited Latest Developments
Table 113. Beijing Health Guard Biotechnology Inc. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 115. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Beijing Health Guard Biotechnology Inc. Main Business
Table 117. Beijing Health Guard Biotechnology Inc. Latest Developments
Table 118. CSL Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 120. CSL Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. CSL Limited Main Business
Table 122. CSL Limited Latest Developments
Table 123. Emergent BioSolutions Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 125. Emergent BioSolutions Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Emergent BioSolutions Main Business
Table 127. Emergent BioSolutions Latest Developments
Table 128. Sanofi Pasteur Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 130. Sanofi Pasteur Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Sanofi Pasteur Main Business
Table 132. Sanofi Pasteur Latest Developments
Table 133. Serum Institute Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 135. Serum Institute Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Serum Institute Main Business
Table 137. Serum Institute Latest Developments
LIST OF FIGURES
Figure 1. Picture of Human Genetically Engineered Vaccine
Figure 2. Human Genetically Engineered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Genetically Engineered Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Human Genetically Engineered Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Human Genetically Engineered Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Genetic Recombinant Vaccine
Figure 12. Product Picture of Recombinant Subunit Vaccines
Figure 13. Product Picture of Genetic Vaccine
Figure 14. Global Human Genetically Engineered Vaccine Sales Market Share by Type in 2026
Figure 15. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Human Genetically Engineered Vaccine Consumed in Hepatitis E
Figure 17. Global Human Genetically Engineered Vaccine Market: Hepatitis E (2021-2026) & (K Units)
Figure 18. Human Genetically Engineered Vaccine Consumed in Human Papillomavirus (HPV)
Figure 19. Global Human Genetically Engineered Vaccine Market: Human Papillomavirus (HPV) (2021-2026) & (K Units)
Figure 20. Human Genetically Engineered Vaccine Consumed in Rotavirus
Figure 21. Global Human Genetically Engineered Vaccine Market: Rotavirus (2021-2026) & (K Units)
Figure 22. Human Genetically Engineered Vaccine Consumed in Others
Figure 23. Global Human Genetically Engineered Vaccine Market: Others (2021-2026) & (K Units)
Figure 24. Global Human Genetically Engineered Vaccine Sale Market Share by Application (2025)
Figure 25. Global Human Genetically Engineered Vaccine Revenue Market Share by Application in 2026
Figure 26. Human Genetically Engineered Vaccine Sales by Company in 2026 (K Units)
Figure 27. Global Human Genetically Engineered Vaccine Sales Market Share by Company in 2026
Figure 28. Human Genetically Engineered Vaccine Revenue by Company in 2026 ($ millions)
Figure 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Company in 2026
Figure 30. Global Human Genetically Engineered Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 33. Americas Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 34. APAC Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 35. APAC Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 36. Europe Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 37. Europe Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 40. Americas Human Genetically Engineered Vaccine Sales Market Share by Country in 2026
Figure 41. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Figure 42. Americas Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 43. Americas Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 44. United States Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Human Genetically Engineered Vaccine Sales Market Share by Region in 2026
Figure 49. APAC Human Genetically Engineered Vaccine Revenue Market Share by Region (2021-2026)
Figure 50. APAC Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 51. APAC Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 52. China Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. India Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Human Genetically Engineered Vaccine Sales Market Share by Country in 2026
Figure 60. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Figure 61. Europe Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 62. Europe Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 63. Germany Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. France Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 71. Egypt Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine in 2026
Figure 77. Manufacturing Process Analysis of Human Genetically Engineered Vaccine
Figure 78. Industry Chain Structure of Human Genetically Engineered Vaccine
Figure 79. Channels of Distribution
Figure 80. Global Human Genetically Engineered Vaccine Sales Market Forecast by Region (2027-2032)
Figure 81. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Human Genetically Engineered Vaccine
Figure 2. Human Genetically Engineered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Genetically Engineered Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Human Genetically Engineered Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Human Genetically Engineered Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Genetic Recombinant Vaccine
Figure 12. Product Picture of Recombinant Subunit Vaccines
Figure 13. Product Picture of Genetic Vaccine
Figure 14. Global Human Genetically Engineered Vaccine Sales Market Share by Type in 2026
Figure 15. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Human Genetically Engineered Vaccine Consumed in Hepatitis E
Figure 17. Global Human Genetically Engineered Vaccine Market: Hepatitis E (2021-2026) & (K Units)
Figure 18. Human Genetically Engineered Vaccine Consumed in Human Papillomavirus (HPV)
Figure 19. Global Human Genetically Engineered Vaccine Market: Human Papillomavirus (HPV) (2021-2026) & (K Units)
Figure 20. Human Genetically Engineered Vaccine Consumed in Rotavirus
Figure 21. Global Human Genetically Engineered Vaccine Market: Rotavirus (2021-2026) & (K Units)
Figure 22. Human Genetically Engineered Vaccine Consumed in Others
Figure 23. Global Human Genetically Engineered Vaccine Market: Others (2021-2026) & (K Units)
Figure 24. Global Human Genetically Engineered Vaccine Sale Market Share by Application (2025)
Figure 25. Global Human Genetically Engineered Vaccine Revenue Market Share by Application in 2026
Figure 26. Human Genetically Engineered Vaccine Sales by Company in 2026 (K Units)
Figure 27. Global Human Genetically Engineered Vaccine Sales Market Share by Company in 2026
Figure 28. Human Genetically Engineered Vaccine Revenue by Company in 2026 ($ millions)
Figure 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Company in 2026
Figure 30. Global Human Genetically Engineered Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 33. Americas Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 34. APAC Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 35. APAC Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 36. Europe Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 37. Europe Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Human Genetically Engineered Vaccine Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Human Genetically Engineered Vaccine Revenue 2021-2026 ($ millions)
Figure 40. Americas Human Genetically Engineered Vaccine Sales Market Share by Country in 2026
Figure 41. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Figure 42. Americas Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 43. Americas Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 44. United States Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Human Genetically Engineered Vaccine Sales Market Share by Region in 2026
Figure 49. APAC Human Genetically Engineered Vaccine Revenue Market Share by Region (2021-2026)
Figure 50. APAC Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 51. APAC Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 52. China Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. India Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Human Genetically Engineered Vaccine Sales Market Share by Country in 2026
Figure 60. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country (2021-2026)
Figure 61. Europe Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 62. Europe Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 63. Germany Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. France Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Application (2021-2026)
Figure 71. Egypt Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Human Genetically Engineered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine in 2026
Figure 77. Manufacturing Process Analysis of Human Genetically Engineered Vaccine
Figure 78. Industry Chain Structure of Human Genetically Engineered Vaccine
Figure 79. Channels of Distribution
Figure 80. Global Human Genetically Engineered Vaccine Sales Market Forecast by Region (2027-2032)
Figure 81. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Application (2027-2032)
